Journal of Clinical Oncology, Vol 18, Issue 9
(May), 2000: 1888-1899
© 2000 American Society for Clinical Oncology
Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study
By John M. Maris,
Matthew J. Weiss,
Chun Guo,
Robert B. Gerbing,
Daniel O. Stram,
Peter S. White,
Michael D. Hogarty,
Erik P. Sulman,
Patricia M. Thompson,
John N. Lukens,
Katherine K. Matthay,
Robert C. Seeger,
Garrett M. Brodeur
From the Department of Pediatrics, University of Pennsylvania School of Medicine and Children’s Hospital of Philadelphia, Philadelphia, PA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; Departments of Pediatrics and Preventive Medicine, University of Southern California School of Medicine, Los Angeles; Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco; and Children’s Cancer Group, Arcadia, CA.
Address reprint requests to John M. Maris, MD, Children’s Cancer Group, PO Box 60012, Arcadia, CA 91066-6012; email brodeur@ email.chop.edu.
PURPOSE: To determine the independent prognostic significance of 1p36 loss of heterozygosity (LOH) in a representative group of neuroblastoma patients.
PATIENTS AND METHODS: Diagnostic tumor specimens from 238 patients registered onto the most recent Children’s Cancer Group phase III clinical trials were assayed for LOH with 13 microsatellite polymorphic markers spanning chromosome band 1p36. Allelic status at 1p36 was correlated with other prognostic variables and disease outcome.
RESULTS: LOH at 1p36 was detected in 83 (35%) of 238 neuroblastomas. There was a correlation of 1p36 LOH with age at diagnosis greater than 1 year (P = .026), metastatic disease (P < .001), elevated serum ferritin level (P < .001), unfavorable histopathology (P < .001), and MYCN oncogene amplification (P < .001). LOH at 1p36 was associated with decreased event-free survival (EFS) and overall survival (OS) probabilities (P < .0001). For the 180 cases with single-copy MYCN, 1p36 LOH status was highly correlated with decreased EFS (P = .0002) but not OS (P = .1212). Entering 1p36 LOH into a multivariate regression model suggested a trend toward an independent association with decreased EFS (P = .0558) but not with decreased OS (P = .3687). Furthermore, allelic status at 1p36 was the only prognostic variable that was significantly associated with decreased EFS in low-risk neuroblastoma patients (P = .0148).
CONCLUSION: LOH at 1p36 is independently associated with decreased EFS, but not OS, in neuroblastoma patients. Determination of 1p36 allelic status may be useful for predicting which neuroblastoma patients with otherwise favorable clinical and biologic features are more likely to have disease progression.
This article has been cited by other articles:
|
|
|
|
 
N. Ikegaki, T. Gotoh, B. Kung, J. S. Riceberg, D. Y. Kim, H. Zhao, E. F. Rappaport, S. L. Hicks, R. C. Seeger, and X. X. Tang
De novo Identification of MIZ-1 (ZBTB17) Encoding a MYC-Interacting Zinc-Finger Protein as a New Favorable Neuroblastoma Gene
Clin. Cancer Res.,
October 15, 2007;
13(20):
6001 - 6009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Asgharzadeh, R. Pique-Regi, R. Sposto, H. Wang, Y. Yang, H. Shimada, K. Matthay, J. Buckley, A. Ortega, and R. C. Seeger
Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification.
J Natl Cancer Inst,
September 6, 2006;
98(17):
1193 - 1203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Wang, S. Diskin, E. Rappaport, E. Attiyeh, Y. Mosse, D. Shue, E. Seiser, J. Jagannathan, S. Shusterman, M. Bansal, et al.
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
Cancer Res.,
June 15, 2006;
66(12):
6050 - 6062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-O. Henrich, M. Fischer, D. Mertens, A. Benner, R. Wiedemeyer, B. Brors, A. Oberthuer, F. Berthold, J. S. Wei, J. Khan, et al.
Reduced Expression of CAMTA1 Correlates with Adverse Outcome in Neuroblastoma Patients
Clin. Cancer Res.,
January 1, 2006;
12(1):
131 - 138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. F. Attiyeh, W. B. London, Y. P. Mosse, Q. Wang, C. Winter, D. Khazi, P. W. McGrady, R. C. Seeger, A. T. Look, H. Shimada, et al.
Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma.
N. Engl. J. Med.,
November 24, 2005;
353(21):
2243 - 2253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Maris, G. Hii, C. A. Gelfand, S. Varde, P. S. White, E. Rappaport, S. Surrey, and P. Fortina
Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform
Genome Res.,
August 1, 2005;
15(8):
1168 - 1176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tajiri, X. Liu, P. M. Thompson, S. Tanaka, S. Suita, H. Zhao, J. M. Maris, G. C. Prendergast, and M. D. Hogarty
Expression of a MYCN-interacting Isoform of the Tumor Suppressor BIN1 Is Reduced in Neuroblastomas with Unfavorable Biological Features
Clin. Cancer Res.,
August 1, 2003;
9(9):
3345 - 3355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn
Advances in the Diagnosis and Treatment of Neuroblastoma
Oncologist,
June 1, 2003;
8(3):
278 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Wang, G. Hii, S. Shusterman, Y. Mosse, C. L. Winter, C. Guo, H. Zhao, E. Rappaport, M. D. Hogarty, and J. M. Maris
ID2 Expression Is not Associated with MYCN Amplification or Expression in Human Neuroblastomas
Cancer Res.,
April 1, 2003;
63(7):
1631 - 1635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Spitz, B. Hero, K. Ernestus, and F. Berthold
Deletions in Chromosome Arms 3p and 11q Are New Prognostic Markers in Localized and 4s Neuroblastoma
Clin. Cancer Res.,
January 1, 2003;
9(1):
52 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chlenski, S. Liu, S. E. Crawford, O. V. Volpert, G. H. DeVries, A. Evangelista, Q. Yang, H. R. Salwen, R. Farrer, J. Bray, et al.
SPARC Is a Key Schwannian-derived Inhibitor Controlling Neuroblastoma Tumor Angiogenesis
Cancer Res.,
December 15, 2002;
62(24):
7357 - 7363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Hogarty, C. L. Winter, X. Liu, C. Guo, P. S. White, A. T. Look, G. M. Brodeur, and J. M. Maris
No Evidence for the Presence of an Imprinted Neuroblastoma Suppressor Gene within Chromosome Sub-Band 1p36.3
Cancer Res.,
November 15, 2002;
62(22):
6481 - 6484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Maris, M. J. Weiss, Y. Mosse, G. Hii, C. Guo, P. S. White, M. D. Hogarty, T. Mirensky, G. M. Brodeur, T. R. Rebbeck, et al.
Evidence for a Hereditary Neuroblastoma Predisposition Locus at Chromosome 16p12-13
Cancer Res.,
November 15, 2002;
62(22):
6651 - 6658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N Bown
Neuroblastoma tumour genetics: clinical and biological aspects
J. Clin. Pathol.,
December 1, 2001;
54(12):
897 - 910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lastowska, C. Cullinane, S. Variend, S. Cotterill, N. Bown, S. O'Neill, K. Mazzocco, P. Roberts, J. Nicholson, C. Ellershaw, et al.
Comprehensive Genetic and Histopathologic Study Reveals Three Types of Neuroblastoma Tumors
J. Clin. Oncol.,
June 15, 2001;
19(12):
3080 - 3090.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Takeuchi, S. Nicole, A. Misaki, M. Furihata, J. Iwata, H. Sonobe, and Y. Ohtsuki
Expression of SMARCF1, a Truncated Form of SWI1, in Neuroblastoma
Am. J. Pathol.,
February 1, 2001;
158(2):
663 - 672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Thompson, J. M. Maris, M. D. Hogarty, R. C. Seeger, C. P. Reynolds, G. M. Brodeur, and P. S. White
Homozygous Deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma
Cancer Res.,
January 1, 2001;
61(2):
679 - 686.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. K. Matthay
MYCN Expression in Neuroblastoma: A Mixed Message?
J. Clin. Oncol.,
November 1, 2000;
18(21):
3591 - 3594.
[Full Text]
[PDF]
|
|
|
|
